The US-based Roswell Park Cancer Institute has begun a Phase I/IIa clinical trial on a new adoptive T-cell therapy for the treatment of various types of advanced cancer.
Called TGF-beta, the trial is based on a new two-step immunotherapy strategy designed to aid the immune system in effectively attacking tumour cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will include 24 patients who will have their T-cells removed using a process similar to that of platelet removal. Patients will then be given enhanced super T-cells, which contain an added component to help more effectively target and suppress cancer cells.
A single injection of enhanced T-cells will be administered in around one week. The injected T-cells are intended to act through a perpetual cell renewal and expansion process.
Roswell Park Immunotherapy centre associate director Richard Koya said: “It’s an approach that allows the immune system to be on the offense and on the defence at the same time.
“First we arm the T-cells with a receptor to help them hunt down the cancer cells, and then we add a TGF-beta blocker to suppress the suppressor.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The result of this two-step gene modification, forcing expression of the receptor for NY-ESO-1, and adding a blocker gene to nullify the effect of TGF-beta is a super T-cell engineered to both more effectively kill target cancer cells and to resist the tumour’s attack.”
In preclinical studies, the new therapy was found to be effective, long-lasting, and well-tolerated.
